1. Normal renal function 8 to 13 years after Cyclosporin A therapy in 285 diabetic patients
- Author
-
Gilles Feutren, Françoise Blanchet, Roger Assan, Claude Amiel, Jean-François Bach, Etienne Larger, José Timsit, and Christian Boitard
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Endocrinology, Diabetes and Metabolism ,Urology ,Renal function ,PAH clearance ,Kidney ,Kidney Function Tests ,Autoimmune Diseases ,Nephropathy ,Nephrotoxicity ,Endocrinology ,Pregnancy ,Diabetes mellitus ,Cyclosporin a ,Internal Medicine ,Humans ,Medicine ,business.industry ,Inulin ,medicine.disease ,Surgery ,Proteinuria ,Diabetes Mellitus, Type 1 ,medicine.anatomical_structure ,Creatinine ,Hypertension ,Cyclosporine ,Female ,Kidney Diseases ,Vascular Resistance ,business ,Immunosuppressive Agents ,Follow-Up Studies ,Glomerular Filtration Rate ,Kidney disease - Abstract
Background Cyclosporin A (CyA) may induce acute nephrotoxicity. The question has been raised of the possible long-term unfavorable course of CyA-induced lesions. Advantage was taken of a large cohort of diabetic patients treated for several months using moderate CyA dosage to evaluate the long-term evolution of renal function in such patients. Methods Two hundred and eighty five recently diagnosed type 1 diabetic patients having received CyA for a mean of 19.9 months were monitored for 13 years, in parallel with 100 similar patients treated with insulin alone. Results In the CyA-treated group, a transient increase in creatininemia levels occurred during the first 18 months of treatment associated with a transient increase in renal vascular resistance. Both effects disappeared later on: creatininemia levels then remained normal. Inulin and p-aminohippurate (PAH) clearances remained normal throughout follow-up. Neither permanent renal failure nor progressive deterioration of renal function occurred in either group or in individual patients. A 10 to 12% increase in inulin and PAH clearance was elicited by IV amino acid infusion at 7 to 10 years, a finding consistent with a normal renal functional reserve. Patients with moderate kidney lesions on biopsy at 1 year had normal and stable clearance values at 7 to 13 years. The prevalence of arterial hypertension and retinopathy was lower in the CyA-treated group than in the control group, possibly because of the tighter metabolic control obtained in the CyA group. Conclusion These results suggest that low-dose CyA treatment combined with thorough monitoring does not result in long-term renal dysfunction. Copyright © 2002 John Wiley & Sons, Ltd.
- Published
- 2002
- Full Text
- View/download PDF